Exploration of antibody-drug conjugates reveals their potential to improve survival rates in metastatic UC, indicating new treatment pathways.
Urothelial carcinoma (UC) is the 9th most common and the 13th most deadly cancer worldwide[1][1]. Despite the availability of platinum-based chemotherapy and immune checkpoint inhibitors (ICIs), the 5-year survival rate of patients with metastatic UC (mUC) remains poor (10–15%)[2][2]. Antibody-
No takes yet. Share an insight, caveat, or question.
Wei et al. (2025) studied this question.